Could a 15-Day pill stop breast cancer before it starts?
NCT ID NCT02928978
First seen Apr 24, 2026 · Last updated May 04, 2026 · Updated 2 times
Summary
This study tested whether the drug ruxolitinib can reduce abnormal cells in people with high-risk breast conditions like atypical hyperplasia or ductal carcinoma in situ (DCIS). Half of the 84 participants took ruxolitinib for about 15 days before surgery, while the other half took a placebo. Researchers compared cell death in breast tissue samples taken before and after treatment to see if the drug had an effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCTAL CARCINOMA IN SITU are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harris Health System - Smith Clinic
Houston, Texas, 77054, United States
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
O'Quinn Medical Tower - McNair Campus; Dan L Duncan Comprehensive Cancer Center
Houston, Texas, 77054, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.